Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
Jie Tang(Xihua University), Yongsheng Wang(Guangzhou University of Chinese Medicine)
Cited by 27
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model
|Molecular Medicine Reports|2015|53
Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
|Frontiers in Oncology|2021|31